
Dr. Placeholder A
HPCSA MP0XXXXX
General Practice
“Cannabis medicine sits inside primary care — same diligence, same record-keeping, same patient relationship.”
HPCSA-registeredSAHPRA-authorisedPOPIA-secure
3–7 day end-to-end · ZA only

Our panel
Every doctor on the Docto24 panel is HPCSA-registered, has Section 21 experience, and prescribes independently. We facilitate the consultation; the clinical decision belongs to the doctor.

Dr. Placeholder A
HPCSA MP0XXXXX
General Practice
“Cannabis medicine sits inside primary care — same diligence, same record-keeping, same patient relationship.”

Dr. Placeholder B
HPCSA MP0XXXXX
Pain Medicine
“For chronic pain that has not responded to first-line therapy, a structured cannabinoid trial deserves consideration.”

Dr. Placeholder C
HPCSA MP0XXXXX
Psychiatry
“Cannabinoids are an adjunct, not a replacement, for evidence-based psychiatric care. The boundary matters.”

Dr. Placeholder D
HPCSA MP0XXXXX
Neurology
“In treatment-resistant epilepsy and MS spasticity, the cannabinoid evidence base is now strong enough to discuss seriously.”

Dr. Placeholder E
HPCSA MP0XXXXX
Palliative Care
“In palliative oncology, symptom relief is the goal. Cannabinoids earn their place when they deliver it.”

Dr. Placeholder F
HPCSA MP0XXXXX
Internal Medicine
“A complete medication review comes first. Then we talk about whether a Section 21 product fits the picture.”
Real names, photos, and HPCSA numbers go live with the public launch. The placeholder cards above represent the actual specialties on our panel. Each doctor’s registration is independently verifiable on the HPCSA register.
How we vet our doctors
Every doctor presents a current HPCSA registration in good standing. We verify the registration number directly with the Health Professions Council before adding them to the panel.
We require demonstrated experience filing Section 21 applications. Doctors who have never filed under Section 21 do not join the panel — there is no learning curve at the patient’s expense.
Cannabinoid medicine is a moving field. Panel doctors commit to ongoing CPD in cannabinoid pharmacology and the evolving SAHPRA framework, and to participating in our internal case review.
Begin the eligibility assessment — we route you to the right specialty automatically.